G-Csf (Filgrastim, Amgen)


Indications and Reactions:

Role Indications Reactions
Secondary
Diffuse Large B-cell Lymphoma 35.5%
Acute Lymphocytic Leukaemia 19.4%
Acute Myeloid Leukaemia 9.7%
Neuroblastoma 9.7%
Breast Cancer 6.5%
Leukaemia 6.5%
Endometrial Cancer Stage Iv 3.2%
Multiple Myeloma 3.2%
Myelodysplastic Syndrome 3.2%
Sarcoma 3.2%
Vomiting 17.9%
White Blood Cell Count Decreased 15.2%
Pyrexia 9.7%
Neutropenia 6.9%
Thrombocytopenia 6.2%
Staphylococcal Infection 4.8%
Tachycardia 4.8%
Febrile Neutropenia 4.1%
Pneumonia 3.4%
Sepsis 2.8%
Septic Shock 2.8%
Stomatitis 2.8%
Tachypnoea 2.8%
Tremor 2.8%
Venoocclusive Liver Disease 2.8%
Diarrhoea 2.1%
Pain 2.1%
Pulmonary Embolism 2.1%
Respiratory Failure 2.1%
Stem Cell Transplant 2.1%

Drug Data